Macro
Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.
Home
tech
energy
finance
healthcare
defense
industrial
consumer
communication
utilities
real estate
raw materials
← back
healthcare · sector mood
1997
year mood
+0.36
· +0.20 to +0.40 across 12 mo
Monthly mood
bearish −1
+1 bullish
month values ▾
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0.40 | +0.40 | +0.40 | +0.40 | +0.40 | +0.40 | +0.40 | +0.40 | +0.38 | +0.20 | +0.30 | +0.30 |
A booming pharma bull year, but September's FDA-forced fen-phen withdrawal over heart-valve damage hit Wyeth/AHP with enormous liability and re-introduced litigation risk; the October Asian-crisis wobble was cushioned by my defensiveness.
How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or
makes their living in it: how am I feeling this month, and why?
The month's mood is that running answer, tied to the specific events driving it (the story shown
above). It leans on trusted, higher-impact reporting, and on the prior month when a month is
quiet, so one loud headline can't swing it. The read updates daily through
the month; once a month ends, its mood is locked.
This year is read live from the news the pipeline actually collected (hover a bar for its story count).
· last computed Jul 06, 2026
Top healthcare stories of 1997
Sep
FDA withdraws fen-phen drugs over heart valve risks
deseret.com →
The FDA requested withdrawal of diet drugs Redux and Pondimin due to links to heart valve damage, affecting the fen-phen combination therapy. Wyeth-Ayerst agreed to halt sales, prompting market concerns over drug safety and potential litigation, while phentermine remains available but no longer part of the combo regimen.